Form 4: Protagonist Therapeutics CEO Sells Shares to Cover Tax Obligations

Dinesh V. Patel, CEO of Protagonist Therapeutics, sold 5,359 shares of common stock on February 19, 2025, to cover tax withholding obligations.

Summary

• On February 19, 2025, Dinesh V. Patel, the President and CEO of Protagonist Therapeutics, Inc. [PTGX], sold 5,359 shares of common stock.
• The sale was executed at a price of $38.18 per share.
• The transaction was conducted to cover tax withholding obligations incurred upon the settlement of restricted stock units.
• Following the transaction, Patel directly owns 540,260 shares of Protagonist Therapeutics, Inc.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing relates to a routine stock sale for tax purposes, with no indication of significant positive or negative implications for the company.

Industry Context

This is a routine Form 4 filing, indicating a transaction by a company insider. Such filings are common and provide transparency into the trading activities of company executives and directors. The sale appears to be related to tax obligations, which is a typical reason for insider sales.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the stated reason for the sale.

Key Dates

Keywords

Form 4, Protagonist Therapeutics, PTGX, Dinesh V. Patel, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership, Insider Trading